Chapter 1: INTRODUCTION

1.1. Report description
1.2. Key benefits to Stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porters five forces analysis

3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in the Incidences of Acute Lymphoblastic Leukemia
3.4.1.2. Rise in Number of New Product Approvals

3.4.2. Restraints

3.4.2.1. Patent Expiry of Blockbuster Drugs
3.4.2.2. Side effects of the treatment

3.4.3. Opportunity

3.4.3.1. Increase in number of Clinical Trials

Chapter 4: ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pediatric

4.2.1. Market size and forecast

4.3. Adult

4.3.1. Market size and forecast

Chapter 5: ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

5.1. Overvie

5.1.1. Market size and forecast

5.2. Hyper-CVAD regimen

5.2.1. Market size and forecast

5.3. Linker regimen

5.3.1. Market size and forecast

5.4. Nucleoside metabolic inhibitors (Clolar and Nelarabine)

5.4.1. Market size and forecast

5.5. Targeted drugs & immunotherapy

5.5.1. Market size and forecast

5.6. CALGB 8811 regimen

5.6.1. Market size and forecast

5.7. Oncaspar

5.7.1. Market size and forecast

Chapter 6: ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities

6.3. Europe

6.3.1. Key market trends and opportunities

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities

6.5. LAMEA

6.5.1. Key market trends and opportunities

Chapter 7: COMPANY PROFILES

7.1. AMGEN, INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BRISTOL-MYERS SQUIBB COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. ERYTECH PHARMA

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Key strategic moves and developments

7.4. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. NOVARTIS AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. PFIZER, INC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. RARE DISEASE THERAPEUTICS, INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. SANOFI

7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Product portfolio
7.8.4. Business performance

7.9. SPECTRUM PHARMACEUTICALS, INC

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments